Last reviewed · How we verify
NCT04146805
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BLD-0409 in Healthy Subjects
Phase 1 trial testing BLD-0409 in Chronic Liver Disease in 80 participants. Completed in 12 April 2021.
3 December 2020
Quick facts
| Lead sponsor | Blade Therapeutics |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 80 |
| Start date | 10 January 2020 |
| Primary completion | 3 December 2020 |
| Estimated completion | 12 April 2021 |
| Sites | 1 location across Australia |
Drugs / interventions tested
- BLD-0409 — full drug profile →
- Control: Placebo — full drug profile →
Conditions studied
- Chronic Liver Disease — all drugs for Chronic Liver Disease →
- NASH - Nonalcoholic Steatohepatitis — all drugs for NASH - Nonalcoholic Steatohepatitis →
Sponsor
Blade Therapeutics — full company profile →
Who can join
Adults 18 to 55, any sex, with Chronic Liver Disease or NASH - Nonalcoholic Steatohepatitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Phase 1a, Double Blind, Placebo-Controlled, Single-Center, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability Pharmacokinetics, and Pharmacodynamics of BLD-0409 in Healthy Volunteers
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Commonalities Between ARDS, Pulmonary Fibrosis and COVID-19: The Potential of Autotaxin as a Therapeutic Target.
Ntatsoulis K, Karampitsakos T, Tsitoura E, Stylianaki EA, et al · · 2021 · cited 36× · PMID 34671341 · DOI 10.3389/fimmu.2021.687397 -
Emerging Roles of Lysophosphatidic Acid in Macrophages and Inflammatory Diseases.
Jiang S, Yang H, Li M. · · 2023 · cited 23× · PMID 37569902 · DOI 10.3390/ijms241512524
Verify or expand the search:
- PubMed search for NCT04146805
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of BLD-0409
Trials testing the same drug.
- NCT04814472 — Healthy Volunteer Study Comparing Tablet and Oral Solution Formulations · Phase 1 · completed
- NCT04814498 — Drug-Drug Interaction (DDI) Study in Healthy Volunteers · Phase 1 · completed
Other recruiting trials for Chronic Liver Disease
Currently open trials in the same condition.
- NCT06592820 — Endoscopic Ultrasound Shear Wave Elastography Study · recruiting
- NCT06318949 — Albumin Modifications as Early Biomarkers of Chronic Liver Diseases · NA · recruiting
- NCT06743464 — Effect of Perioperative Oral Rifaximin on Early Graft Dysfunction in Adult Living Donor Liver Transplant · NA · recruiting
- NCT06587568 — Mobile Chat Messaging for Alcohol Reduction in Patients With Chronic Liver Diseases · NA · active not recruiting
- NCT06493799 — In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Pl · Phase 3 · recruiting
Other Blade Therapeutics trials
Trials by the same sponsor.
- NCT05373914 — RESPIRARE - Efficacy and Safety of Cudetaxestat in Patients With Idiopathic Pulmonary Fibrosis (IPF) · Phase 2 · unknown
- NCT04939467 — Dedicated Drug-Drug Interaction (DDI) Study in Healthy Volunteers · Phase 1 · completed
- NCT04814472 — Healthy Volunteer Study Comparing Tablet and Oral Solution Formulations · Phase 1 · completed
- NCT04814498 — Drug-Drug Interaction (DDI) Study in Healthy Volunteers · Phase 1 · completed
- NCT04334460 — Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04146805 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Blade Therapeutics
- Last refreshed: 4 June 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04146805.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing